Dexcom Reports Second Quarter 2026 Financial Results
Article excerpt
Highlighted: the sentence this signal was extracted from
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights: Second Quarter 2026 Strategic Highlights: "During the quarter, we had the opportunity to host many of you at our 2026 Investor Day, where we highlighted our substantial market opportunity and introduced a new long-term financial outlook through 2030," said Jake Leach, Dexcom's president and CEO. "This quarter's performance and the successful outcomes from our CONNECT trial reinforce our confidence in the path ahead and position us well to deliver on our long-range plan." 2026 Annual Guidance Dexcom is raising the midpoint of fiscal year 2026 Revenue guidance and increasing fiscal year 2026 guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin to the following levels: ____________________ Second Quarter 2026 Financial Results Revenue: In the second quarter of 2026, worldwide revenue grew 13% to $1.308 billion on a reported basis, up from $1.157 billion in the second quarter of 2025. Gross Profit: GAAP gross profit totaled $830.0 million or 63.4% of revenue for the second quarter of 2026, compared to $688.8 million or 59.5% of revenue in the second quarter of 2025. Non-GAAP gross profit* totaled $838.5 million or 64.1% of reported revenue for the second quarter of 2026, compared to...
Keep reading with a free account
The rest of this article, and every signal for Dexcom, is in your free account.